Information Provided By: 
Fly News Breaks for December 11, 2018
VNDA
Dec 11, 2018 | 07:27 EDT
As previously reported, Oppenheimer analyst Esther Rajavelu downgraded Vanda Pharmaceuticals to Perform from Outperform saying that with the tasimelteon Smith-Magenis Syndrome trial meeting one of the two primary endpoints, the stock fairly reflects the inherent risk/reward at current trading levels. The analyst will await on the sidelines the publication of the results and an update on the regulatory strategy post the pre-NDA meeting.
News For VNDA From the Last 2 Days
